Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities

Area of Science:

• Virology
• Drug Repurposing
• Infectious Diseases

Background:

• The COVID-19 pandemic caused by SARS-CoV-2 necessitates urgent development of effective therapeutics.
• Vaccine roll-out challenges highlight the need for alternative treatment strategies.
• Repurposed FDA-approved drugs with known safety profiles are being investigated for COVID-19 treatment.

Purpose of the Study:

• To review the identification of ivermectin (IVM) as a potential COVID-19 therapeutic.
• To explore the molecular mechanisms underlying IVM's antiviral activity against SARS-CoV-2.
• To summarize current clinical findings on ivermectin for COVID-19 treatment.

Main Methods:

• Literature review of SARS-CoV-2 lifecycle and viral protein functions.
• Analysis of historical research identifying potential antiviral properties of ivermectin.
• Examination of ivermectin's molecular mechanism of action against SARS-CoV-2.
• Compilation and review of current clinical trial data for ivermectin in COVID-19 patients.

Main Results:

• Ivermectin, initially an antiparasitic, demonstrated in vitro antiviral activity against SARS-CoV-2.
• Research identified key molecular targets and mechanisms for ivermectin's action against the virus.
• Clinical studies are evaluating the efficacy and safety of ivermectin as a COVID-19 treatment.

Conclusions:

• Ivermectin presents a potential therapeutic option for COVID-19, supported by preclinical and emerging clinical data.
• Further clinical investigation is crucial to establish ivermectin's definitive role in managing COVID-19.
• The repurposing of ivermectin exemplifies a viable strategy for rapidly addressing viral pandemics.